Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(33%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
8%
Ph phase_2
10
83%
Ph phase_3
1
8%

Phase Distribution

1

Early Stage

10

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
10(83.3%)
Phase 3Large-scale testing
1(8.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

12

all time

Status Distribution
Active(8)
Completed(1)
Other(3)

Detailed Status

Not yet recruiting4
Recruiting4
unknown3
Completed1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
4
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (8.3%)
Phase 210 (83.3%)
Phase 31 (8.3%)

Trials by Status

not_yet_recruiting433%
recruiting433%
completed18%
unknown325%

Recent Activity

Clinical Trials (12)

Showing 12 of 12 trials
NCT07449481Phase 2

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Not Yet Recruiting
NCT06764940Phase 2

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Recruiting
NCT06102824Phase 2

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting
NCT06683703Phase 2

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

Not Yet Recruiting
NCT06510465Phase 2

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Not Yet Recruiting
NCT06125080Phase 2

The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) :Single-arm, Prospective, Open Clinical Study

Recruiting
NCT05983094Phase 2

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not Yet Recruiting
NCT05430399Phase 3

Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer

Recruiting
NCT05052437Phase 1

PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Completed
NCT05357417Phase 2

Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases

Unknown
NCT05403333Phase 2

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Unknown
NCT05299255Phase 2

Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer

Unknown

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12